Pharming Operating Cycle from 2010 to 2026
| PHAR Stock | USD 20.59 0.59 2.79% |
Operating Cycle | First Reported 2010-12-31 | Previous Quarter 597.01 | Current Value 567.16 | Quarterly Volatility 472.68171393 |
Check Pharming Group financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Pharming Group's main balance sheet or income statement drivers, such as Depreciation And Amortization of 19.4 M, Interest Expense of 6.8 M or Selling And Marketing Expenses of 6.1 M, as well as many indicators such as Price To Sales Ratio of 2.43, Dividend Yield of 0.0 or PTB Ratio of 3.82. Pharming financial statements analysis is a perfect complement when working with Pharming Group Valuation or Volatility modules.
Pharming | Operating Cycle | Build AI portfolio with Pharming Stock |
Evaluating Pharming Group's Operating Cycle across multiple reporting periods reveals the company's ability to sustain growth and manage resources effectively. This longitudinal analysis highlights inflection points, cyclical patterns, and structural changes that short-term snapshots might miss, offering deeper insight into Pharming Group NV's fundamental strength.
Latest Pharming Group's Operating Cycle Growth Pattern
Below is the plot of the Operating Cycle of Pharming Group NV over the last few years. It is Pharming Group's Operating Cycle historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Pharming Group's overall financial position and show how it may be relating to other accounts over time.
| Operating Cycle | 10 Years Trend |
|
Operating Cycle |
| Timeline |
Pharming Operating Cycle Regression Statistics
| Arithmetic Mean | 804.53 | |
| Geometric Mean | 673.70 | |
| Coefficient Of Variation | 58.75 | |
| Mean Deviation | 393.49 | |
| Median | 597.01 | |
| Standard Deviation | 472.68 | |
| Sample Variance | 223,428 | |
| Range | 1.5K | |
| R-Value | (0.39) | |
| Mean Square Error | 202,649 | |
| R-Squared | 0.15 | |
| Significance | 0.12 | |
| Slope | (36.22) | |
| Total Sum of Squares | 3.6M |
Pharming Operating Cycle History
About Pharming Group Financial Statements
Pharming Group shareholders use historical fundamental indicators, such as Operating Cycle, to determine how well the company is positioned to perform in the future. Although Pharming Group investors may analyze each financial statement separately, they are all interrelated. The changes in Pharming Group's assets and liabilities, for example, are also reflected in the revenues and expenses on on Pharming Group's income statement. Understanding these patterns can help investors time the market effectively. Please read more on our fundamental analysis page.
| Last Reported | Projected for Next Year | ||
| Operating Cycle | 597.01 | 567.16 |
Pair Trading with Pharming Group
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Pharming Group position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Pharming Group will appreciate offsetting losses from the drop in the long position's value.Moving together with Pharming Stock
Moving against Pharming Stock
| 0.8 | KG | Kestrel Group Symbol Change | PairCorr |
| 0.78 | ENSC | Ensysce Biosciences | PairCorr |
| 0.71 | OGEN | Oragenics | PairCorr |
| 0.58 | XBIO | Xenetic Biosciences | PairCorr |
| 0.35 | ORIC | Oric Pharmaceuticals | PairCorr |
The ability to find closely correlated positions to Pharming Group could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Pharming Group when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Pharming Group - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Pharming Group NV to buy it.
The correlation of Pharming Group is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Pharming Group moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Pharming Group NV moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Pharming Group can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Additional Tools for Pharming Stock Analysis
When running Pharming Group's price analysis, check to measure Pharming Group's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Pharming Group is operating at the current time. Most of Pharming Group's value examination focuses on studying past and present price action to predict the probability of Pharming Group's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Pharming Group's price. Additionally, you may evaluate how the addition of Pharming Group to your portfolios can decrease your overall portfolio volatility.